Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evogene ( (EVGN) ) has provided an update.
On March 5, 2026, Evogene reported its fourth-quarter and full-year 2025 results, highlighting a strategic overhaul that consolidated the business around its ChemPass AI engine for small-molecule discovery in pharma and agriculture and exited non-core activities. The company integrated AgPlenus into its core operations, curtailed Casterra’s Kenyan seed business, and saw subsidiaries Lavie Bio and Biomica effectively wound down following the 2025 sale of Lavie Bio’s operations to ICL and the early-2026 out-licensing of Biomica’s lead oncology asset, with both units expected to return excess cash to shareholders.
The restructuring produced a sharp reduction in operating expenses to about $13.8 million in 2025 from $22.0 million in 2024, even as revenue fell to $3.9 million from $5.6 million due mainly to lower AgPlenus and Casterra contributions and a one-time 2024 payment. Evogene ended 2025 with roughly $13.0 million in cash and supplemented liquidity in February 2026 via a $3.4 million warrant inducement deal, while absorbing a $2.2 million Casterra inventory impairment that drove cost of revenues higher, signaling a leaner but more tightly focused platform business for investors and partners.
The most recent analyst rating on (EVGN) stock is a Hold with a $0.98 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
Spark’s Take on EVGN Stock
According to Spark, TipRanks’ AI Analyst, EVGN is a Neutral.
Evogene’s overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. While the earnings call provided some positive insights into cost management and strategic initiatives, the company’s financial instability and bearish technical indicators weigh heavily on the score.
To see Spark’s full report on EVGN stock, click here.
More about Evogene
Evogene Ltd., based in Rehovot, Israel, operates in computational chemistry, using generative AI to design novel small molecules for pharmaceutical and agricultural applications. Its ChemPass AI platform underpins partnerships and in-house programs in drug discovery and ag-chem, with subsidiaries such as AgPlenus and Casterra aligned to these core markets.
Average Trading Volume: 448,339
Technical Sentiment Signal: Sell
Current Market Cap: $7.31M
Find detailed analytics on EVGN stock on TipRanks’ Stock Analysis page.